These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35806187)

  • 41. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma.
    Wang CX; Wang TT; Zhang KD; Li MY; Shen QC; Lu SY; Zhang J
    Acta Pharmacol Sin; 2022 Oct; 43(10):2696-2708. PubMed ID: 35352018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
    Tang S; Duan Y; Yuan T; Hu Y; Yuan L; Shen N; Fu Y; Pu C; Wang X; Xu J; Lan X; Zheng Y; Zhou Y; Zhu H; Ding J; Geng M; Huang M
    Pharmacol Res; 2023 Nov; 197():106955. PubMed ID: 37820855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
    Li C; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
    Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
    Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
    Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
    Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
    J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
    Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
    Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of DNA-alkylating pyrrole-imidazole polyamides for anti-cancer drug sensitivity screening in pancreatic ductal adenocarcinoma.
    Tsujimoto A; Matsuo N; Lai X; Inoue T; Yoda H; Lin J; Shinozaki Y; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Med; 2023 Mar; 12(5):5821-5832. PubMed ID: 36262061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
    Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
    Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
    Wagner S; Vlachogiannis G; De Haven Brandon A; Valenti M; Box G; Jenkins L; Mancusi C; Self A; Manodoro F; Assiotis I; Robinson P; Chauhan R; Rust AG; Matthews N; Eason K; Khan K; Starling N; Cunningham D; Sadanandam A; Isacke CM; Kirkin V; Valeri N; Whittaker SR
    Oncogene; 2019 Mar; 38(10):1717-1733. PubMed ID: 30353166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
    Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
    Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
    Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
    Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.